Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose and dose limiting
toxicity of 5-FU in combination with Oxaliplatin delivered via isolated hepatic perfusion.
Phase:
Phase 1
Details
Lead Sponsor:
David Bartlett
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)